Phase 1 Parkinson's Disease Trial, Recruiting NCT07195825 Sponsor: Shanghai Xinzhi BioMed Co., Ltd. Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, Recruiting

NCT07195825
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Parkinson's disease for at least 5 years
  • Your Parkinson's symptoms, measured during an "off" period (when medication is less effective), reach a certain level of severity as assessed by standard rating scales (confirm with trial site)
  • Your symptoms respond positively to a levodopa medication test during an "off" period
  • You have been taking a stable, unchanged dose of Parkinson's medication (such as levodopa) throughout the screening period
  • You agree to delay any brain surgery related to your Parkinson's treatment during the main part of the study
  • You agree not to join any other treatment studies during this trial
  • You agree not to receive any vaccines during the main part of the study
  • You are willing and able to use reliable contraception from the screening period until at least 52 weeks after receiving the study treatment
  • You are able to attend regular follow-up appointments and accurately fill in daily diary cards (a family member, guardian, or caregiver may help with this)
  • You are willing to take part voluntarily and have signed a consent form

Who may not be able to join:

  • You have a form of Parkinsonism that is not typical Parkinson's disease, or your Parkinson's is caused by another condition
  • You have reasons why surgery would not be safe for you, or you have previously had brain surgery
  • Your brain MRI scan shows something unusual that suggests a condition other than Parkinson's disease
  • You have severe problems with memory or thinking
  • You have severe depression or severe anxiety
  • You have abnormal liver function results
  • You have abnormal blood clotting results
  • You have abnormal results from infectious disease screening tests
  • You are currently receiving antiviral treatment for hepatitis
  • You have an unstable or serious condition affecting your heart, lungs, digestive system, nervous system, blood, immune system, or other major body systems
  • You have or have had a cancer diagnosis
  • You have a history of severe allergic reactions
  • You have taken part in another clinical trial within the past three months
  • You have previously received gene therapy
  • You have received stem cell treatment within the past 12 months
  • You have used another experimental drug within the past 4 weeks
  • You received a live vaccine within the past 2 months, or any vaccine within the past 30 days, during the screening period
  • You have a history of alcohol dependence or drug addiction
  • You are pregnant or breastfeeding
  • The trial doctor decides for any other reason that this trial is not appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jun Liu, MD, Ruijin Hospital

Phone: 021-33588288

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shanghai Xinzhi BioMed Co., Ltd.
Registry
ClinicalTrials.gov
Start date
27 December 2025
Est. completion
30 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of dose limiting toxicity (DLT) events; Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov